Equillium’s (NYSE:EQ) lock-up period will expire on Wednesday, April 10th. Equillium had issued 4,670,000 shares in its IPO on October 12th. The total size of the offering was $65,380,000 based on an initial share price of $14.00. After the expiration of the company’s lock-up period, company insiders and major shareholders will be able to sell their shares of the company.
EQ has been the topic of a number of recent analyst reports. Leerink Swann started coverage on Equillium in a report on Friday, February 22nd. They set an “outperform” rating on the stock. Svb Leerink restated an “outperform” rating and issued a $16.00 target price on shares of Equillium in a research report on Friday, February 22nd. Finally, Zacks Investment Research upgraded shares of Equillium from a “sell” rating to a “hold” rating in a research note on Wednesday, January 16th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $19.00.
Equillium stock opened at $7.46 on Friday. Equillium has a 12-month low of $5.50 and a 12-month high of $19.69.
Equillium (NYSE:EQ) last posted its quarterly earnings data on Wednesday, March 27th. The company reported ($0.31) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.29) by ($0.02).
Several hedge funds have recently modified their holdings of EQ. American International Group Inc. acquired a new stake in shares of Equillium in the fourth quarter valued at $28,000. Deutsche Bank AG acquired a new position in Equillium during the fourth quarter worth about $54,000. Partner Investment Management L.P. acquired a new position in Equillium during the fourth quarter worth about $64,000. Geode Capital Management LLC bought a new stake in Equillium in the fourth quarter worth about $143,000. Finally, Dean Capital Investments Management LLC bought a new stake in Equillium in the fourth quarter worth about $175,000.
ILLEGAL ACTIVITY WARNING: This news story was reported by Stock Observer and is the sole property of of Stock Observer. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of international trademark and copyright laws. The legal version of this news story can be read at https://www.thestockobserver.com/2019/04/07/equilliums-eq-lock-up-period-will-end-on-april-10th.html.
Equillium Company Profile
Equillium, Inc, a biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is EQ001, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1 clinical trials for the treatment of acute graft-versus-host disease and asthma.
Recommended Story: What is a balanced fund?
Receive News & Ratings for Equillium Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Equillium and related companies with MarketBeat.com's FREE daily email newsletter.